公众号 / 文章中毒与环境急症消化、代谢与肾脏急症

利托那韦酶抑制致他克莫司毒性

Tacrolimus toxicity due to enzyme inhibition from ritonavir.
PubMed 文献 · Am J Emerg Med · 2023-05-05
一句话结论急诊医生须警惕奈玛特韦/利托那韦与他克莫司的药物相互作用,近期用药者应评估他克莫司毒性。

本文报告一例85岁肾移植女性,近期诊断COVID-19后接受奈玛特韦/利托那韦治疗,因酶抑制导致他克莫司毒性,就诊急诊时表现为乏力、意识模糊加重、进食差和无法行走,伴脱水和急性肾损伤(肌酐2.1 mg/dL,基线0.8 mg/dL)。初始他克莫司浓度为143 ng/mL(参考范围5-20 ng/mL),停用后仍继续上升至住院第3天峰值189 ng/mL。使用苯妥英进行酶诱导后他克莫司浓度开始下降,住院17天后转至康复机构。作者强调急诊医生在处方奈玛特韦/利托那韦及评估近期用药患者时须认知药物相互作用以识别毒性。

要点

  • 85岁肾移植女性近期用奈玛特韦/利托那韦后出现他克莫司毒性,初始浓度143 ng/mL(参考5-20 ng/mL),停用他克莫司后仍升至住院第3天峰值189 ng/mL。
  • 急诊表现为乏力、意识模糊加重、进食差、无法行走,伴脱水和急性肾损伤(肌酐2.1 mg/dL,基线0.8 mg/dL)。
  • 使用苯妥英进行酶诱导后他克莫司浓度开始下降,住院17天后转至康复机构。
  • 急诊医生处方奈玛特韦/利托那韦及评估近期用药患者时须认知药物相互作用,以识别由此导致的毒性。

适用人群与场景

  • 有实体器官移植史、正在使用他克莫司等免疫抑制剂的COVID-19患者,尤其因基础合并症和免疫抑制而接受奈玛特韦/利托那韦早期治疗者。

处置流程与药物剂量

  • 对近期使用奈玛特韦/利托那韦的移植患者,急诊应检测他克莫司浓度:本例初始143 ng/mL(参考范围5-20 ng/mL),停用他克莫司后仍升至住院第3天峰值189 ng/mL。
  • 本例使用苯妥英进行酶诱导后,他克莫司浓度开始下降。

红旗征与不能漏的情况

  • 移植患者使用奈玛特韦/利托那韦后出现乏力、意识模糊加重、进食差、无法行走,需警惕他克莫司毒性。
  • 伴脱水及急性肾损伤(肌酐2.1 mg/dL,基线0.8 mg/dL)时,他克莫司浓度可继续上升,即使已停用他克莫司。

研究设计与关键结果

  • 病例报告:85岁女性,有多次合并症及肾移植史,因乏力、意识模糊加重、进食差、无法行走至急诊;近期诊断COVID-19并因基础合并症和免疫抑制接受奈玛特韦/利托那韦。
  • 急诊查体脱水,急性肾损伤(肌酐2.1 mg/dL,基线0.8 mg/dL);初始他克莫司浓度143 ng/mL(参考范围5-20 ng/mL),停用后仍上升至住院第3天峰值189 ng/mL。
  • 使用苯妥英酶诱导后他克莫司浓度开始下降;住院17天后转至康复机构。

证据类型、等级与局限

  • 证据类型:病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊医生在处方奈玛特韦/利托那韦时须认知其药物相互作用,评估近期使用该药的患者以识别由此导致的毒性。
  • 对使用他克莫司的移植患者,近期奈玛特韦/利托那韦暴露应促使检测他克莫司浓度,即使已停用他克莫司,浓度仍可能继续上升。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Tacrolimus is commonly used for immunosuppression in patients following solid organ transplantation. For transplant patients with COVID-19 infection, early treatment is indicated due to the risk of progression to severe disease. However, the first line agent, nirmatrelvir/ritonavir, has multiple drug-drug interactions. We report a case of tacrolimus toxicity in a patient with a history of renal transplant due to enzyme inhibition related to nirmatrelvir/ritonavir. An 85-year-old woman with a history of multiple comorbidities presented to the emergency department (ED) with weakness, increasing confusion, poor oral intake, and inability to walk. She had been recently diagnosed with COVID-19 infection and was prescribed nirmatrelvir/ritonavir due to her underlying comorbidities and immune suppression. In the ED, she was dehydrated and had an acute kidney injury (creatinine 2.1 mg/dL, up from a baseline of 0.8 mg/dL). The tacrolimus concentration on initial labs was 143 ng/mL (5-20 ng/mL) and it continued to rise despite being held, to a peak of 189 ng/mL on hospital day 3. The patient was treated with phenytoin for enzyme induction and the tacrolimus concentration began to fall. She was discharged to a rehabilitation facility after a 17 day hospitalization. ED physicians must be cognizant of drug-drug interactions when prescribing nirmatrelvir/ritonavir and evaluating patients recently treated with the drug to identify toxicity due to these interactions.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Snee I, Drobina J, Mazer-Amirshahi M, et al. Tacrolimus toxicity due to enzyme inhibition from ritonavir. Am J Emerg Med. 2023. PMID: 37173153. doi:10.1016/j.ajem.2023.04.045

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。